For local staging of bladder tumour, MRI has superior soft tissue contrast resolution compared with CT and can evaluate post-biopsy reaction as enhancement of the tumour occurs earlier than that of the normal bladder wall due to neovascularisation. #BladderCancer #EAUguidelines

🎓 Medical students — it’s your turn! Join us for the Radiology in Medical School SIG, an open and interactive session for students interested in diagnostic imaging. 🗓 October 7, 2025 | 8–9:30 PM (BRT) 💻 Free online event @CBRadiologia

📍 Brasília Institutional agenda at the Federal Council of Medicine (@medicina_cfm ). Collective work toward a new resolution. #Medicine #Ethics #Radiology

Confira meu artigo mais recente: Estratégias práticas para integrar radiologia e especialidades clínicas https://t.co/xfRxWGUkG5 via @LinkedIn

@marcelogusmao2 @CassiaTamura @giga_fra @mauzappa @FennessyFiona @SchuchAlice Day 2: GU refresher course Quick updates: - Testis → germ cell tumors, staging. - Penis → MRI differentiates superficial vs invasive disease. - Kidney → Bosniak v2019 for cystic lesions, focal tumors. - Adrenal → incidentalomas vs malignancy, imaging pathways.

@marcelogusmao2 @CassiaTamura @giga_fra @mauzappa @FennessyFiona @SchuchAlice Day 2: Imaging advances in bladder cancer - VI-RADS anticipates stage & guides treatment decisions. - Strong evidence (AUC 0.92–0.94, BladderPath trial). - Guidelines: EAU 2024 endorses MRI for staging. - Pitfalls remain: bladder distension, pseudodiverticulum, stalk.

@marcelogusmao2 @CassiaTamura @giga_fra @mauzappa @FennessyFiona Day 2: Urothelial tumors - Upper tract tumors: risk stratification guides therapy; radiologist role is central. - VI-RADS validated, reproducible, easy to use → supports bladder cancer staging. - Post-treatment follow-up: nacVI-RADS promising after neoadjuvant chemo.

@marcelogusmao2 @CassiaTamura @giga_fra @mauzappa Prostate cancer imaging (Day 1) - PET-PSMA revolutionized staging & recurrence, guiding therapy (incl. ¹⁷⁷Lu-PSMA). - PRIME trial → bpMRI non-inferior to mpMRI (shorter, cheaper, no contrast). - New scores (PI-QUAL, PRECISE, PI-RR) & AI integration = future direction.

@marcelogusmao2 @CassiaTamura @giga_fra Prostate Imaging (Day 1) - Screening: MRI can reduce PSA-related; quality is crucial. - Active surveillance: MRI + targeted biopsy mandatory; re-biopsies may be reduced, not eliminated. - Post focal therapy: MRI is key to monitor recurrence.

Arena Radiologists of the Future (Day 1) 👉 Radiologists must go beyond reporting. Clinical leadership, financial awareness & well-being (time management, mindfulness, sports) are essential for a sustainable career.

Highlights from the first 2 days at #CBR2025 in Curitiba 🇧🇷. Prostate MRI, PET-PSMA, VI-RADS, imaging biomarkers, AI and also radiologists’ well-being. 🧵 Key points below:

🚨 PRIME is out! 🚨 The trial, just published in JAMA, shows #bpMRI is non-inferior to #mpMRI for #ProstateCancer detection when performed with high-quality imaging & expert radiologists. A key step to expand MRI access for men at risk. Honored to be part of this journey.

📚 Just defended my Executive MBA in Healthcare Management thesis at @hosp_einstein: “Expansion with Excellence: scaling a high-complexity imaging network in Brazil.” Key insight → Strategy • Culture • People, sustained by adaptive governance & applied innovation.

@SocietyAbdRad @EsurOffice 📅 Sept 18–20 | Curitiba, Brazil 📍 GU Module – #CBR2025 🔗 Program: https://t.co/Fwuid6huMA @CBRadiologia

A major highlight: international faculty from @SocietyAbdRad & @EsurOffice . A unique opportunity for knowledge exchange, practice alignment & strengthening collaboration networks.

The GU track will cover: 🔹 Prostate MRI (quality, PI-RADS updates, active surveillance) 🔹 Bladder cancer imaging (VI-RADS, staging, follow-up) 🔹 Renal & adrenal tumors – practical workflows & new evidence 🔹 Integration of imaging into oncologic decision-making

⏳ The countdown has begun: #CBR2025 in Curitiba, Brazil. I am honored to co-chair the Genitourinary scientific program with @SchuchAlice & Ronaldo Hueb Baroni, under @mauzappa’ direction.

💬 Associate Professor @veerukasi (@UCLDivofSurgery), lead researcher: “Around four million MRI scans are needed each year to diagnose prostate cancer […] If we can do the scan in up to half the time, with fewer staff and at lower cost, that will make a huge difference.”

🌍 Implications bpMRI offers a faster, cheaper, safer exam. With ~4M prostate MRIs/year worldwide, adoption could reshape diagnostic pathways, expand access & reduce costs. #ProstateMRI #CancerImaging #Radiology

💡 Contrast (DCE) sequences: •New suspicious areas: 6.3% •Changed eligibility: 4.3% •Changed treatment planning: 3.1%